BR0212846A - Agentes antimicrobianos fotodinâmicos de porfirina - Google Patents

Agentes antimicrobianos fotodinâmicos de porfirina

Info

Publication number
BR0212846A
BR0212846A BR0212846-2A BR0212846A BR0212846A BR 0212846 A BR0212846 A BR 0212846A BR 0212846 A BR0212846 A BR 0212846A BR 0212846 A BR0212846 A BR 0212846A
Authority
BR
Brazil
Prior art keywords
porphyrins
porphyrin
antimicrobial agents
photodynamic
bacteria
Prior art date
Application number
BR0212846-2A
Other languages
English (en)
Portuguese (pt)
Inventor
Jerry Bommer
Giulio Jori
Original Assignee
Frontier Scient Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Frontier Scient Inc filed Critical Frontier Scient Inc
Publication of BR0212846A publication Critical patent/BR0212846A/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/22—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains four or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/409—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil having four such rings, e.g. porphine derivatives, bilirubin, biliverdine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0057—Photodynamic therapy with a photosensitizer, i.e. agent able to produce reactive oxygen species upon exposure to light or radiation, e.g. UV or visible light; photocleavage of nucleic acids with an agent
    • A61K41/0071—PDT with porphyrins having exactly 20 ring atoms, i.e. based on the non-expanded tetrapyrrolic ring system, e.g. bacteriochlorin, chlorin-e6, or phthalocyanines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR0212846-2A 2001-09-26 2002-06-26 Agentes antimicrobianos fotodinâmicos de porfirina BR0212846A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/964,286 US6573258B2 (en) 2000-09-27 2001-09-26 Photodynamic porphyrin antimicrobial agents
PCT/US2002/020148 WO2003026646A1 (en) 2001-09-26 2002-06-26 Photodynamic porphyrin antimicrobial agents

Publications (1)

Publication Number Publication Date
BR0212846A true BR0212846A (pt) 2004-10-13

Family

ID=25508357

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0212846-2A BR0212846A (pt) 2001-09-26 2002-06-26 Agentes antimicrobianos fotodinâmicos de porfirina

Country Status (11)

Country Link
US (1) US6573258B2 (zh)
EP (1) EP1429758A4 (zh)
JP (1) JP4698948B2 (zh)
CN (1) CN1257712C (zh)
AU (1) AU2002322316B2 (zh)
BR (1) BR0212846A (zh)
CA (1) CA2459928C (zh)
IL (2) IL160743A0 (zh)
MX (1) MXPA04002783A (zh)
RU (1) RU2004109160A (zh)
WO (1) WO2003026646A1 (zh)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6127356A (en) 1993-10-15 2000-10-03 Duke University Oxidant scavengers
WO1999023097A1 (en) * 1997-11-03 1999-05-14 Duke University Substituted porphyrins
DK1616869T3 (da) 1999-01-25 2012-05-07 Nat Jewish Health Substituerede porphyriner og deres terapeutiske anvendelse
AU2002312194B8 (en) * 2001-06-01 2008-05-15 Aeolus Sciences, Inc. Oxidant scavengers for treatment of diabetes or use in transplantation or induction of immune tolerance
WO2003103680A1 (en) * 2002-06-07 2003-12-18 Duke University Substituted porphyrins
GB2397067B (en) * 2002-12-23 2005-05-11 Destiny Pharma Ltd Porphin & azaporphin derivatives with at least one cationic-nitrogen-containing meso-substituent for use in photodynamic therapy & in vitro sterilisation
EP1457113A1 (en) * 2003-03-12 2004-09-15 Salbert Co Ltd Alkylated porphyrins as pesticides acting both in the presence and absence of light
US20040259852A1 (en) * 2003-06-18 2004-12-23 White Hillary D. Trandsdermal compositions and methods for treatment of fibromyalgia and chronic fatigue syndrome
US8883769B2 (en) * 2003-06-18 2014-11-11 White Mountain Pharma, Inc. Methods for the treatment of fibromyalgia and chronic fatigue syndrome
WO2006001844A2 (en) * 2004-01-29 2006-01-05 Pinnacle Pharmaceuticals β-CYCLODEXTRIN DERIVATIVES AND THEIR USE AGAINST ANTHRAX LETHAL TOXIN
US20080234182A1 (en) * 2007-03-22 2008-09-25 Innovative Biologics, Inc. Blockers of pore-forming virulence factors and their use as anti-infectives
MXPA06011244A (es) * 2004-03-29 2007-04-13 Inotek Pharmaceuticals Corp Compuestos de porfirina sustituida por piridilo, y metodos de uso de los mismos.
WO2005120573A2 (en) * 2004-06-07 2005-12-22 Yeda Research And Development Co. Ltd. Cationic bacteriochlorophyll derivatives and uses thereof
GB2415372A (en) 2004-06-23 2005-12-28 Destiny Pharma Ltd Non photodynamical or sonodynamical antimicrobial use of porphyrins and azaporphyrins containing at least one cationic-nitrogen-containing substituent
JP2009510083A (ja) * 2005-09-28 2009-03-12 イノテック ファーマシューティカルズ コーポレイション Ｎ−ベンジル置換ピリジルポルフィリン化合物およびその使用方法
US20090030257A1 (en) * 2007-07-25 2009-01-29 Ceramoptec Industries Inc. Anti-microbial photodynamic therapy
EP2732817B1 (en) 2008-05-23 2016-08-24 National Jewish Health A compound for use in treating injury associated with exposure to phosgene or chlorine gas
US8859760B2 (en) 2008-07-29 2014-10-14 Frontier Scientific, Inc. Compositions for killing or preventing the growth of microbes
MX2011001005A (es) * 2008-07-29 2011-09-01 Frontier Scient Inc Uso de derivados de tetraquis (n-alquilpiridinio)-porfirina para eliminacion de microbios o prevencion del crecimiento.
EP2442641A4 (en) * 2009-06-16 2016-03-09 Univ Columbia METHOD FOR REDUCING SIDE EFFECTS OF THE TRANSFUSION OF AGED RED BLOOD CELLS
IT1402153B1 (it) 2010-10-08 2013-08-28 Uni Degli Studi Camerino Composizione comprendente un larvicida fotoattivabile
CN102167704B (zh) * 2011-03-20 2014-05-14 扬州大学 水溶性卟啉金（ⅲ）抗癌化合物及其制备方法
US8626106B2 (en) 2011-12-06 2014-01-07 Tensorcom, Inc. Method and apparatus of an input resistance of a passive mixer to broaden the input matching bandwidth of a common source/gate LNA
FR2987259B1 (fr) * 2012-02-29 2014-02-21 Oreal Utilisation comme agent antipelliculaire de composes catalytiques d'oxydation choisi parmi les porphyrines, les phthalocyanines et les porphyrazines
ES2664411T3 (es) 2013-03-15 2018-04-19 Suncor Energy Inc. Composiciones herbicidas
EP2835054A1 (en) 2013-08-05 2015-02-11 Nimartech Limited Porphyrinoid compounds, method and apparatus for water photodisinfection.
RU2549953C2 (ru) * 2013-12-25 2015-05-10 Федеральное государственное унитарное предприятие Государственный научный центр "Научно-исследовательский институт органических полупродуктов и красителей" (ФГУП "ГНЦ "НИОПИК") Фотосенсибилизатор для фотодинамической терапии
PL3200582T3 (pl) 2014-09-29 2024-04-08 Fred Hutchinson Cancer Center Kompozycje, zestawy i sposoby indukcji nabytej cytororoporności z wykorzystaniem induktorów białek stresowych
WO2016108083A1 (en) * 2014-12-31 2016-07-07 University Of Oslo Eutectic solvents and uses thereof
CN104862373B (zh) * 2015-06-11 2018-01-02 河北工业大学 一种高通量筛选光动力抗菌光敏剂的方法
WO2019033216A1 (en) * 2017-08-16 2019-02-21 Suncor Energy Inc. PHOTODYNAMIC INHIBITION OF MICROBIAL PATHOGENIC AGENTS IN PLANTS
WO2020163965A1 (en) * 2019-02-15 2020-08-20 Suncor Energy Inc. Photosensitizer and chelating agent combinations for use as insecticides
CN115006582B (zh) * 2022-07-18 2023-06-02 南通大学 一种抗炎抗氧化纳米敷料及其制备方法
CN116003820B (zh) * 2023-02-15 2023-12-19 山东大学 一种基于钯卟啉和三蝶烯的多孔有机聚合物及其制备方法与应用
CN117327210B (zh) * 2023-12-01 2024-02-02 潍坊医学院 一种基于β-环糊精对苯二甲醛包合物的卟啉微孔复合材料及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0434727A4 (en) * 1988-09-08 1994-08-17 Ultra Diagnostic Corp Red-shifted phthalocyanine and tetrabenztriazaporphyrin reagents
GB9114290D0 (en) * 1991-07-02 1991-08-21 Courtaulds Plc Polymer compositions
DE19962505A1 (de) * 1999-12-23 2001-07-05 Schaffer Moshe Mikrobizide Wirkung von Porphyrinen im Dunkeln
JP3425111B2 (ja) * 2000-01-26 2003-07-07 科学技術振興事業団 イオン性ポルフィリン化合物

Also Published As

Publication number Publication date
US6573258B2 (en) 2003-06-03
EP1429758A4 (en) 2006-08-30
IL160743A (en) 2010-02-17
JP2005505574A (ja) 2005-02-24
CN1558760A (zh) 2004-12-29
CN1257712C (zh) 2006-05-31
US20030050296A1 (en) 2003-03-13
CA2459928C (en) 2010-03-23
WO2003026646A1 (en) 2003-04-03
JP4698948B2 (ja) 2011-06-08
MXPA04002783A (es) 2005-04-08
RU2004109160A (ru) 2005-03-10
CA2459928A1 (en) 2003-04-03
AU2002322316B2 (en) 2006-07-13
EP1429758A1 (en) 2004-06-23
IL160743A0 (en) 2004-08-31

Similar Documents

Publication Publication Date Title
BR0212846A (pt) Agentes antimicrobianos fotodinâmicos de porfirina
MX166955B (es) Composicion absorbente de luz ultravioleta
EA200000391A1 (ru) Производные тиенопиримидина и тиенопиридина, полезные в качестве противораковых агентов
ATE204602T1 (de) Photodynamische inaktivierung von viren in zellenzusammensetzungen
ES2162198T3 (es) Agentes estrogenos.
RU94038064A (ru) Производные пиперазина и пиперидина, их применение в качестве противопсихотических средств, способ их получения фармацевтическая композиция
EA200800375A1 (ru) Соединения и способы ингибирования экспрессии vcam-1
PT1420824E (pt) Clorinas sulfonadas como fotossensibilizadores
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
EA199900936A1 (ru) Фунгицидные трифторметилалкиламинотриазолопиримидины
EA200200616A1 (ru) Химические производные и их применение в качестве антителомеразного агента
EA199900749A1 (ru) Фармацевтическая композиция
PT896533E (pt) Pentafluorobenzenosulfonamidas e analogos
EA200100204A1 (ru) Фармацевтические агенты для лечения болезни паркинсона, ганв и микроаденом
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
AR036472A1 (es) Derivados de azetidina, procedimientos para su preparacion y su empleo como agentes pesticidas
ES2148593T3 (es) Compuestos retinoides trienoicos novedosos y metodos.
BR0012696A (pt) Composição oftálmica
DE69713300T2 (de) Benzopyran derivate mit leukotrien-antagonistischer wirkung
DE69434356D1 (de) Inclusion-Komplex von Beta-Cyclodextrin mit Diclofenac
EA199900385A1 (ru) Соединения 1-арил-2-ациламиноэтана и их применение в качестве антагонистов нейрокинина, в частности нейрокинина 1
CO5190674A1 (es) Tratamiento de desordenes neuroticos desordenes neuroticos
AR024747A1 (es) Derivados de aminotiazoles, su preparacion y las composiciones farmaceuticas que los contienen.
EA200100947A1 (ru) Жевательные таблетки с высоким содержанием n-ацетилцистеина
RU94038042A (ru) Производные гексагидроазепинов, фармацевтическая композиция на их основе и антипсихотропный агент

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PARA: INT. CL. A61K 31/409, 31/4439; C07D 487/22; A61P 31/04, 31/00

Ipc: A61K 31/409 (2011.01), A61K 31/4439 (2011.01), C07

B15V Prolongation of time limit allowed

Free format text: RECONHECIDO O OBSTACULO ADMINISTRATIVO E DEVOLVIDO O PRAZO DE 31 DIAS PARA CUMPRIMENTO DE EXIGENCIA, NOS TERMOS DO ARTIGO 221 PARAGRAFO 2O DA LPI E DA RESOLUCAO 116/04.

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS ANUIDADES EM DEBITO.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2316 DE 26-05-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.